Peripheral T-cell lymphomas (PTCL) accounted for about 5% of all non-Hodgkin’s lymphomas. Standard first line treatment is with combination chemotherapy but the majority of patients relapse. There is no standard treatment for refractory or relapsed disease. However, histone deacetylase inhibitors, panabinostat and romidepsin, and pralatrexate are licensed for use...